A 68-year-old male has been treated with prednisolone and intravenous immunoglobulin (IVIG) therapies with the diagnosis of pemphigus vulgaris. When he applied to receive the fifth session of IVIG therapy, he complained about visual loss. On the ophthalmologic examination, left central retinal vein occlusion (CRVO) was determined. There was no other detected underlying cause for CRVO and it was thought that central retinal vein thrombosis might be due to IVIG therapy.
Pemphigus vulgaris is a life-threatening autoimmune bullous disease. Adjuvant treatments are needed because of serious side effects of traditional treatments such as high-dose, long-term systemic steroids or because of no response to treatment. Intravenous immunoglobulin treatment (IVIG) is generally accepted reliable. But it can cause rarely serious side effects like thrombosis (1) . To our knowledge, there are a few central retinal vein occlusion (CRVO) cases in the literature due to IVIG treatment. We present a case of CRVO following intravenous immunoglobulin treatment for pemphigus vulgaris.
Case report
A 68-year-old male has been treated with prednisolone (onset dose was 120 mg/day) and azathiopurine (150 mg/day) with the diagnosis of pemphigus vulgaris one year ago. But, azathiopurine was stopped by the gastroenterology department because of the increase of the liver enzymes. The patient had pain and tremor on the legs and steroid myopathy was diagnosed by neurological examination. Also, after a short time, the patient started to complain about an intense back pain and multiple compression fractures were diagnosed by radiological examination. The patient was treated with stabilitation corset and bed rest. Because of complications related to the steroids, as an adjuvant therapy, we have initiated IVIG treatment, 400 mg/kg/day, with 5 days/month cycles after repeating laboratory tests and the actual steroid 54 therapy has been decreased gradually. When the patient applied us to receive fifth session of IVIG, he has been taking 10 mg prednisolon every other day and had the complaint of visual loss at the left eye. This complaint occured 2 weeks after 4th session. On ophtalmological examination, the vision of left eye was 0.05, biomicroscopic findings were normal. Dilated fundus examination revealed dilated and tortuos retinal veins with patchy retinal hemorrhages, a few cotton wool spots and optic disc edema (Figure 1 ). Intraocular pressure was normal and left CRVO diagnosis was made. Fundus fluorescein angiography and optical coherence tomography confirmed the diagnosis (Figure 2,3) . On general physical examination, blood pressure was 130/80 mmHg and heart rate 72/min and rhytmic. Patient had no smoking, hypertension, cardiovascular disease history. The tests for complete blood count, erythrocyte sedimentation rate (ESR), serum glucose level, hepatic, renal and thyroid functions, lipid profile, blood coagulation profile, antinuclear antikor (ANA), protein C and S activities, lupus anticoagulant, anticardiolipin antibodies, serum protein and immune electrophoresis, homocystein level were all in normal limits. Also, chest radiography, ecocardiography, abdominal ultrasonography and carotid doppler ultrasonography examination revealed no pathology. It was thought that central retinal ven thrombosis might be due to intravenous immunoglobulin therapy. Intravitreal dexamethasone implant was applied by ophthalmology department and the patient was taken under a follow-up period. Because the patient has been still in remission for pemphigus vulgaris about 8 months with IVIG and low-dose systemic steroid and has no other predisposing factor for thrombosis, IVIG therapy has been continued by the permission of ophthalmology department. 5 th application was made 1 month after the intravitreal dexamethasone implant therapy and no other IVIG related complication including thrombosis was determined for 10 months follow-up. Pemphigus vulgaris lesions of the patient is in remission and IVIG therapy has been already administered with 8 weekly periods. (2) (3) (4) (5) (6) . Table 1 shows the summary of these cases.
We think that thrombosis is related with IVIG treatment because he has been taking steroid treatment more than one year and CRVO developed while the patient was having steroid dose as low as 10 mg, every other day. Also, the patient has no thrombosis causing pathologies such as hypertension, hyperlipidemia, coronary artery disease. He has no smoking history. And no diseases related to CRVO such as hypergamaglobulinemia, cyrioglobulinemia and hyperhomocysteinemia are obtained by the laboratory tests. In our case, three weeks after the fourth administration of IVIG visual loss developed, this period was consistent with the literature.
The mechanism of thrombosis due to IVIG treatment is not well understood. One of the possible mechanisms is the increase in viscosity which is dose-dependent and related to duration of treatment (7) . Also it is proposed that IVIG treatment can cause thrombotic occlusions by causing changes in the profiles of cytokine and vasoactive subtances. Human immunoglobulins with dose dependent mechanisms can cause a decrease in nitric oxide production which is triggered by thrombin. Nitric oxide prevents thrombosit aggregation and play an important role in vascular hemostasis by making vasodilatation (8) . Furthermore invivo studies have shown correlation between IVIG adverse reactions and elevated levels of IL-6, a proinflammatory cytokine, and thromboxane, a vasoactive substance (9) . Suchlike alterations in the profile of cytokines and vasoactive substances may have triggered the thrombotic adverse reaction. -Intravenous immunoglobulin treatment is alternative therapy option generally accepted reliable.
-Hovewer, intravenous immunoglobulin treatment can cause rarely serious side effects like thrombosis.
-Central retinal vein occlusion due to intravenous immunoglobulin treatment is extremely rare.
-Especially, the patients who have emerging eye symptoms during the treatment must be evaluated for the possibility of central retinal vein occlusion
